Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole
Abstract Otsuka Pharmaceutical Co., Ltd. successfully developed the first dopamine D2 receptor partial agonist approved for schizophrenia, the antipsychotic aripiprazole (Abilify®). The drug was approved for this indication in the United States in 2002 and has received approval in the United States,...
Main Authors: | Tetsuro Kikuchi, Kenji Maeda, Mikio Suzuki, Tsuyoshi Hirose, Takashi Futamura, Robert D. McQuade |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-06-01
|
Series: | Neuropsychopharmacology Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/npr2.12180 |
Similar Items
-
Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?
by: Pavel Mohr, et al.
Published: (2022-01-01) -
DIURNAL ENURESIS SECONDARY TO ARIPIPRAZOLE
by: Huseyin BAYAZIT
Published: (2017-09-01) -
Post‐hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long‐term study (Secondary Publication)
by: Jun Ishigooka, et al.
Published: (2020-06-01) -
Experience with Dopamine Agonists in the Treatment of Prolactinomas
by: Nadiya Barabash, et al.
Published: (2022-11-01) -
Treating Patients with Aripiprazol: A Safe Gamble?
by: B. Leal, et al.
Published: (2022-06-01)